RESUMEN
The study aimed to create a low loading, high retention, easier to apply O/W mometasone furoate (MF) cream using a chemical enhancer (CE) approach to provide more options for patients with atopic dermatitis (AD) and to investigate molecular mechanisms of its increased release and retention. A Box-Behnken design determined the optimal formulation based on stability and in vitro skin retention. Evaluations included appearance, rheological properties, irritation, in vivo tissue distribution and pharmacodynamics. Molecular mechanisms of enhanced release were studied using high-speed centrifugation, molecular dynamics and rheology. The interaction between the CE, MF and skin was studied by tape stripping, CLSM, ATR-FTIR and SAXS. The formulation was optimized to contain 0.05% MF and used 10% polyglyceryl-3 oleate (POCC) as the CE. There was no significant difference from Elocon® cream in in vivo retention and pharmacodynamics but increased in vivo retention by 3.14-fold and in vitro release by 1.77-fold compared to the basic formulation. POCC reduced oil phase cohesive energy density, enhancing drug mobility and release. It disrupted skin lipid phases, aiding drug entry and formed hydrogen bonds, prolonging retention. This study highlights POCC as a CE in the cream, offering insights for semi-solid formulation development.
Asunto(s)
Liberación de Fármacos , Furoato de Mometasona , Crema para la Piel , Piel , Furoato de Mometasona/administración & dosificación , Furoato de Mometasona/farmacocinética , Furoato de Mometasona/química , Animales , Crema para la Piel/administración & dosificación , Crema para la Piel/química , Piel/metabolismo , Piel/efectos de los fármacos , Administración Cutánea , Masculino , Absorción Cutánea/efectos de los fármacos , Química Farmacéutica/métodos , Glicerol/química , Glicerol/análogos & derivados , Dermatitis Atópica/tratamiento farmacológico , Femenino , Excipientes/química , Antiinflamatorios/administración & dosificación , Antiinflamatorios/química , Antiinflamatorios/farmacología , Antiinflamatorios/farmacocinética , Composición de Medicamentos/métodos , Ácido Oléico/química , Polímeros/químicaRESUMEN
We report the development and the validation of a sensitive liquid chromatography-mass spectrometry (LC-MS/MS) method for mometasone furoate (MF) analysis in human plasma. Plasma samples were processed through liquid-liquid extraction and analyzed using LC-MS/MS operating in positive mode using multiple reaction monitoring of transitions m/z 520.9 â 355.0 and m/z 525.8 â 355.0 for MF and the internal standard (IS), respectively. Separation was achieved at 1.0 mL/min on a C18 column using a gradient elution of mobile phase of 0.05% ammonia in water (phase A) and acetonitrile (phase B). The assay range was 0.250-100 pg/mL and proved to be accurate and precise MF. Normalized recoveries were consistent and reproducible with a coefficient of variation (CV%) value of 6.0. The CV (%) of the IS normalized matrix factor was not observed in normal, lipemic, and hemolyzed plasmas. Dilutions of 1:10 were accurately quantified. A cycle of three freeze and thaw and stabilities at room temperature and on the autosampler were demonstrated. In addition, MF in the presence of indacaterol and glycopyrronium was proven to be stable at -70°C for at least 157 days. The present method was successfully applied to quantify MF in patients receiving MF, indacaterol, and glycopyrronium as a fixed-dose combination.
Asunto(s)
Furoato de Mometasona , Espectrometría de Masas en Tándem , Humanos , Furoato de Mometasona/sangre , Furoato de Mometasona/farmacocinética , Furoato de Mometasona/química , Espectrometría de Masas en Tándem/métodos , Reproducibilidad de los Resultados , Cromatografía Liquida/métodos , Modelos Lineales , Sensibilidad y Especificidad , Estabilidad de Medicamentos , Extracción Líquido-Líquido/métodos , Límite de Detección , Cromatografía Líquida con Espectrometría de MasasRESUMEN
Purpose: We designed a 0.05% mometasone furoate (MF) nanocrystal dispersion and investigated whether the application of MF nanocrystals in nasal formulations enhanced local absorption compared to traditional nasal MF formulations (CA-MF). Methods: MF nanocrystal dispersions (MF-NPs) were prepared by bead milling MF microcrystal dispersions (MF-MPs) consisting of MF, 2-hydroxypropyl-ß-cyclodextrin, methylcellulose, and purified water. Pluronic F-127 combined with methylcellulose, Pluronic F-68, or carbopol was used as a base for in situ gelation (thickener). MF concentrations were measured using high-performance liquid chromatography, and nasal absorption of MF was evaluated in 6 week-old male Institute of Cancer Research (ICR) mice. Results: The particle size range of MF prepared with the bead mill treatment was 80-200 nm, and the nanoparticles increased the local absorption of MF, which was higher than that of CA-MF and MF-MPs. In addition, unlike the results obtained in the small intestine and corneal tissue, the high absorption of nanocrystalline MF in the nasal mucosa was related to a pathway that was not derived from energy-dependent endocytosis. Moreover, the application of the in situ gelling system attenuated the local absorption of MF-NPs, owing to a decrease in drug diffusion in the dispersions. Conclusion: We found that nanoparticulation of MF enhances local intranasal absorption, and nasal bioavailability is higher than that of CA-MF. In addition, we demonstrate that viscosity regulation is an important factor in the design of nasal formulations based on MF nanocrystals. These findings provide insights for the design of novel nanomedicines with enhanced nasal bioavailability.
Asunto(s)
Absorción Nasal , Mucosa Nasal , Masculino , Animales , Ratones , Furoato de Mometasona/química , Furoato de Mometasona/uso terapéutico , Mucosa Nasal/metabolismo , MetilcelulosaRESUMEN
Demonstrating bioequivalence (BE) of nasal suspension sprays is a challenging task. Analytical tools are required to determine the particle size of the active pharmaceutical ingredient (API) and the structure of a relatively complex formulation. This study investigated the utility of the morphologically-directed Raman spectroscopy (MDRS) method to investigate the particle size distribution (PSD) of nasal suspensions. Dissolution was also investigated as an orthogonal technique. Nasal suspension formulations containing different PSD of mometasone furoate monohydrate (MFM) were manufactured. The PSD of the MFM batches was characterized before formulation manufacture using laser diffraction and automated imaging. Upon formulation manufacture, the droplet size, single actuation content, spray pattern, plume geometry, the API dissolution rate, and the API PSD by MDRS were determined. A systematic approach was utilized to develop a robust method for the analysis of the PSD of MFM in Nasonex® and four test formulations containing the MFM API with different particle size specifications. Although the PSD between distinct techniques cannot be directly compared due to inherent differences between these methodologies, the same trend is observed for three out of the four batches. Dissolution analysis confirmed the trend observed by MDRS in terms of PSD. For suspension-based nasal products, MDRS allows the measurement of API PSD which is critical for BE assessment. This approach has been approved for use in lieu of a comparative clinical endpoint BE study [1]. The correlation observed between PSD and dissolution rate extends the use of dissolution as a critical analytical tool demonstrating BE between test and reference products.
Asunto(s)
Furoato de Mometasona/farmacocinética , Administración Intranasal , Furoato de Mometasona/administración & dosificación , Furoato de Mometasona/química , Tamaño de la Partícula , Espectrometría Raman , Suspensiones , Equivalencia TerapéuticaRESUMEN
PURPOSE: The purpose of this study is to develop a new PLGA based formulation for microspheres, which aims to release mometasone furoate for one month, so as to improve compliance. METHODS: The microspheres containing mometasone furoate were prepared by oil in water emulsion and solvent evaporation. The microspheres were characterized by surface morphology, shape, size and encapsulation efficiency. The release in vitro was studied in 37°C phosphate buffer, and in vivo, pharmacodynamics and preliminary safety evaluation were conducted in male Sprague Dawley rats. RESULTS: The morphology results showed that the microspheres have a smooth surface, spherical shape and an average diameter of 2.320-5.679µm. The encapsulation efficiency of the microspheres loaded with mometasone furoate was in the range of 53.1% to 95.2%, and the encapsulation efficiency of the microspheres could be greatly affected by the proportion of oil phase to the water phase and other formulation parameters. In vitro release kinetics revealed that drug release from microspheres was through non-Fick's diffusion and PLGA polymer erosion. Pharmacokinetic data showed that the initial release of microspheres was small and then sustained. The results of the pharmacodynamics study fully proved the long-term effectiveness of mometasone furoate microspheres. The results of in vivo safety evaluation showed that the preparation system possessed good in vivo safety. CONCLUSION: This study shows that the microspheres prepared in this study have sufficient ability to stable drug release at least for 35 days, with good efficacy and high safety. In addition, mometasone furoate can be used as a potential candidate drug for 35 days long-term injection.
Asunto(s)
Artritis , Furoato de Mometasona/química , Ácido Poliglicólico , Animales , Artritis/terapia , Preparaciones de Acción Retardada , Masculino , Microesferas , Furoato de Mometasona/farmacología , Tamaño de la Partícula , Ratas , Ratas Sprague-DawleyRESUMEN
The study is focused on the analysis of physicochemical properties of selected nasal sprays of mometasone furoate, and the influence of these properties on aerosol quality and penetration in the pediatric nose. After the determination of drugs surface tension and viscosity, spray geometry and size distribution of aerosol droplets, the topical delivery of each drug to different parts of the pediatric model of the nose with the flexible vestibule was evaluated by colorimetric visualization. All tested drugs are pseudo-plastic liquids, showing some differences in flow consistency constant k (range 714-1422) and flow behavior index n (range 0.16-0.31). At no-flow conditions, all sprays are deposited mainly in the anterior of the nasal cavity and the septum (2-3 cm from the nostril), as a result of inertial impaction of large droplets. The deposition range is slightly influenced by the geometry of the aerosol cloud, which, in turn, depends both on drug properties and the type of the spraying nozzle. Deposition experiments accompanied by the airflow show an enhancement of drug transport to deeper parts of the nasal cavity (up 4-6 cm from the vestibule), and this effect can be attributed to the secondary effects of spreading of the deposited liquid layer along the narrow air passages in the nose. Plume geometry, dose volume and rheological properties of the drug were shown to be important factors in the spray penetration pattern in the pediatric nose. The deepest delivery can be expected for drugs of low viscosity and short aerosol plumes.
Asunto(s)
Aerosoles/química , Aerosoles/metabolismo , Furoato de Mometasona/química , Cavidad Nasal/efectos de los fármacos , Cavidad Nasal/metabolismo , Administración Intranasal/métodos , Niño , Humanos , Rociadores Nasales , Nebulizadores y Vaporizadores , ViscosidadRESUMEN
Nadifloxacin, mometasone furoate and miconazole nitrate are formulated together as a topical antifungal dosage form. In this work, a reversed-phase ultra-performance liquid chromatographic method coupled with a diode array detector (RP-UPLC-DAD) was developed and validated to determine nadifloxacin, mometasone furoate and miconazole nitrate simultaneously in their bulk powder, in pharmaceutical preparation and in spiked human plasma samples. Separation was achieved on an ACQUITY UPLC C18 column of 2.2 µm particle size (2.1 × 100 mm) via isocratic elution using a mobile phase consisting of methanol, acetonitrile and water with ratio (50:20:30; v/v/v) and 0.1 g ammonium acetate, then pH was adjusted to (7.00) using acetic acid, flow rate 0.6 mL/min, temperature 30°C and UV detection at 220 nm. The method is linear in a range from 5 to 400 µg/mL for both nadifloxacin and miconazole nitrate and from 20 to 500 µg/mL for mometasone furoate. The method was validated according to the ICH guidelines then applied successfully to determine the mentioned drugs in their pharmaceutical preparation and spiked human plasma samples. For plasma samples, the results showed that the method can determine nadifloxacin, mometasone furoate and miconazole nitrate in human plasma samples with high accuracy and precision.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Fluoroquinolonas/análisis , Miconazol/análisis , Furoato de Mometasona/análisis , Quinolizinas/análisis , Cromatografía de Fase Inversa , Fluoroquinolonas/sangre , Fluoroquinolonas/química , Humanos , Límite de Detección , Modelos Lineales , Miconazol/sangre , Miconazol/química , Furoato de Mometasona/sangre , Furoato de Mometasona/química , Quinolizinas/sangre , Quinolizinas/química , Reproducibilidad de los ResultadosRESUMEN
There are quite substantial number of impurities related to dexamethasone or mometasone which cannot be made from respective Active Pharmaceutical Ingredients but from common intermediate 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione (12). As such, a robust and economical synthesis of this key intermediate is important for delivering a resilient and economically viable supply chain for these impurities. Therefore, it is critical to have a robust and economically viable process to synthesize the intermediate 12 in good yield and quality. We report here an improved synthesis of 12 and eight impurities related to dexamethasone and mometasone from this common intermediate.
Asunto(s)
Dexametasona/síntesis química , Furoato de Mometasona/síntesis química , Progesterona/química , Dexametasona/química , Conformación Molecular , Furoato de Mometasona/química , Progesterona/síntesis químicaRESUMEN
BACKGROUND: Chronic rhinosinusitis (CRS) patients who fail medical management have few treatment options other than endoscopic sinus surgery (ESS). A novel biodegradable mometasone furoate drug delivery system (LYR-210) providing continuous topical steroid therapy to sinonasal mucosa over 24 weeks was developed to treat unoperated CRS patients who have failed medical management prior to ESS. LYR-210 was designed to slowly expand in the middle meatus, ensuring efficient drug delivery as mucosal swelling reduces. METHODS: A prospective, multicenter, open-label study was conducted in 20 CRS subjects who were determined to be candidates for ESS. Under endoscopic guidance and topical anesthesia, LYR-210 was placed in both middle meatuses. The primary endpoint was product-related serious adverse events (SAEs) at 4 weeks. Additional assessments included plasma drug concentration, morning serum cortisol levels, intraocular pressures (IOPs), and Sino-Nasal Outcome Test (SNOT-22) scores. RESULTS: LYR-210 was successfully placed bilaterally in 20 subjects (12 without nasal polyps and 8 with polyps) in an office setting. There were no product-related SAEs through 24 weeks, at which point 86% of LYR-210 depots were still retained in the middle meatus. Serum cortisol, IOP, and plasma drug concentrations supported systemic safety at all time points tested. Subjects experienced significant reductions in their SNOT-22 scores as early as week 1, and this reduction persisted through week 24 (p < 0.01). Significant symptom improvement was achieved in the SNOT-22 rhinologic, extranasal rhinologic, ear-facial, psychological, and sleep dysfunction subdomains at 24 weeks (p < 0.05). CONCLUSION: LYR-210 is safe and well-tolerated in ESS-naive CRS patients and leads to sustained symptom improvement in patients.
Asunto(s)
Antiinflamatorios/administración & dosificación , Sistemas de Liberación de Medicamentos , Furoato de Mometasona/administración & dosificación , Rinitis/tratamiento farmacológico , Sinusitis/tratamiento farmacológico , Adulto , Anciano , Antiinflamatorios/química , Enfermedad Crónica , Liberación de Fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Furoato de Mometasona/química , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: The aim of the present study was to develop and evaluate nanostructured lipid carrier based topical hydrogel of mometasone furoate for the treatment of psoriasis. METHOD: Drug loaded NLCs were successfully developed by microemulsion technique. Pseudo ternary phase diagrams were constructed using different combinations of surfactant and co-surfactants to study the microemulsion existence range. Different compositions were selected from the phase diagram showing maximum microemulsion region and were converted into NLCs by dilution in water (1:20). The optimized formulation was characterised for droplet size, zeta potential, entrapment efficiency and morphology was studied using Transmission Electron Microscopy. Ex vivo permeation studies were carried out using Wistar rat skin. The potential of this formulation in treating psoriatic inflammation was studied using imiquimod induced skin inflammation animal model. RESULTS: The optimized formulation (F4) has droplet size of 163.2±0.522 nm, zeta potential - 0.086±0.099 mV and entrapment efficiency of 60.0±0.187%. Transmission electron microscopy confirmed spherical shape of nanostructured lipid carrier. Carbopol 940 was used to convert NLC dispersion into NLC based hydrogel to improve its viscosity for topical administration. Drug permeation studies showed prolonged drug release from the NLC based gel as compared to marketed formulation following Higuchi release kinetics. The skin deposition of MF loaded NLC based hydrogel was found to 2.5 fold higher than marketed formulation with primary skin irritation index of 0.20. In vivo studies showed complete clearance of parakeratosis by treatment with the prepared NLC formulation. Accelerated stability studies signify high robustness scale of optimized formulation under one month storage period. CONCLUSION: The prepared NLC based formulation has proved to be a promising carrier system for the treatment of psoriasis.
Asunto(s)
Antiinflamatorios/administración & dosificación , Portadores de Fármacos/administración & dosificación , Hidrogeles/administración & dosificación , Furoato de Mometasona/administración & dosificación , Resinas Acrílicas/administración & dosificación , Resinas Acrílicas/química , Administración Tópica , Animales , Antiinflamatorios/química , Portadores de Fármacos/química , Liberación de Fármacos , Femenino , Hidrogeles/química , Ratones Endogámicos BALB C , Furoato de Mometasona/química , Ácido Oléico/administración & dosificación , Ácido Oléico/química , Psoriasis/tratamiento farmacológico , Ratas Wistar , Piel/efectos de los fármacos , Piel/metabolismo , Absorción Cutánea , Ácidos Esteáricos/administración & dosificación , Ácidos Esteáricos/químicaRESUMEN
Background Mometasone furoate, one of the second generation intranasal corticosteroids, is currently used in suspension form due to its poor solubility. However, this is not favorable for nasal application because of the rapid elimination of the instilled drug from the nasal cavity by mucociliary clearance and delayed onset of action due to the slow dissolution of drug in suspension. Objective The aim of this study was to determine the antiallergic effects of mucoadhesive thermosensitive in situ gel containing mometasone furoate that we developed previously to prolong the contact between the drug and nasal mucosa and to prevent drainage of the formulation in an ovalbumin-induced rat model of allergic rhinitis. Methods An experimental allergic rhinitis model was developed in female Wistar albino rats by intraperitoneal injection of ovalbumin every 2 days for 14 days followed by its repeated intranasal instillation for 7 consecutive days. Intranasal instillation of ovalbumin was continued every other day for 14 days. Mometasone furoate in situ gel (5 µg/10 µl), mometasone furoate suspension (5 µg/10 µl), and physiological saline (10 µl) were administered into the bilateral nasal cavities from day 22 to day 35. Antiallergic effects were evaluated through histopathological evaluation, analysis of ovalbumin-specific serum immunoglobulin E, and a symptom score. Results Mometasone furoate in situ gel significantly decreased the nasal symptoms and ovalbumin-specific serum immunoglobulin E level as compared with mometasone furoate suspension and physiological saline. Additionally, inflammatory histological symptoms such as mucosal edema, vascular dilatation, eosinophil infiltration, and loss of cilia within the nasal mucosa of allergic rhinitis model rats were remarkably improved with the treatment of mometasone furoate in situ gel. Conclusion These results suggest that mometasone furoate in situ gel has a better therapeutic potential for the treatment of allergic rhinitis compared to mometasone furoate suspension.
Asunto(s)
Antialérgicos/administración & dosificación , Modelos Animales de Enfermedad , Furoato de Mometasona/administración & dosificación , Rinitis Alérgica/tratamiento farmacológico , Administración Intranasal , Animales , Antialérgicos/química , Femenino , Geles/química , Inmunoglobulina E/sangre , Furoato de Mometasona/química , Cavidad Nasal/patología , Ovalbúmina/toxicidad , Ratas , Ratas Wistar , Rinitis Alérgica/inducido químicamente , Rinitis Alérgica/patología , Temperatura , Resultado del TratamientoRESUMEN
Laryngeal and tracheal morbidity is a common complication of endotracheal tube (ETT)-based airway management, and manifests as local irritation, inflammation, and edema. Systemic corticosteroids are commonly administered to manage these conditions; however, their efficacy is inadequate and limited by potential severe side effects. In the present study, a steroid delivery system for local therapy was developed to generate relatively high local drug concentrations and to improve drug efficacy. ETTs were coated with electrospun poly (lactic-co-glycolic acid) (PLGA) nanofibers loaded with mometasone furoate (MF), creating a microscale thick layer. MF exhibited sustained release from coated ETTs over 14days in vitro. An in vivo efficacy study in rats demonstrated the therapeutic benefit of MF-coated ETTs over bare ETTs, as measured by reduced laryngeal mucosal thickness and submucosal laryngeal edema. The fiber coating remained intact during tube intubation and extubation, demonstrating good adhesion to the tubes even after 24h in aqueous solution at 37°C. These findings demonstrate the potential of drug-loaded ETTs to revolutionize the standard of care for endotracheal intubation.
Asunto(s)
Antiinflamatorios/administración & dosificación , Sistemas de Liberación de Medicamentos , Intubación Intratraqueal , Furoato de Mometasona/administración & dosificación , Nanofibras , Animales , Antiinflamatorios/química , Liberación de Fármacos , Masculino , Furoato de Mometasona/química , Nanofibras/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/química , Ratas Sprague-DawleyRESUMEN
Two novel stability-indicating TLC densitometric and chemometric methods were developed for the determination of mometasone furoate (MF) in the presence of its alkaline degradation product (MF Deg). The developed TLC densitometric method (Method A) is based on the quantitative densitometric separation of MF from its alkaline degradation product on silica gel 60 F254 and measurement of the bands at 250 nm. The separation was carried out using hexane-chloroform-methanol-acetonitrile (6:6:1:0.3, by volume) as a developing system. A well-resolved and compact bands for (MF) and (MF Deg) at retention factors 0.36 and 0.66, respectively. Good resolution between (MF) and (MF Deg) assured the specificity of the proposed method. The method showed good linearity in the concentration range 0.5-5 µg/band with r2 = 0.9998. The method validation was performed according to ICH guidelines demonstrating to be accurate, precise, robust and sensitive. The LOD and LOQ were found to be 0.21 and 0.63 µg/band for MF, respectively. The developed TLC-densitometric method can be applied for identification and quantitative determination of MF in bulk drug and pharmaceutical dosage forms without any interference from excipients and degradates. Method B is a multivariate chemometric-assisted spectrophotometry, where classical least squares, principal component regression and partial least squares were applied. Statistical analysis of the results has been carried out revealing high accuracy and good precision.
Asunto(s)
Cromatografía en Capa Delgada/métodos , Furoato de Mometasona/análisis , Furoato de Mometasona/química , Estabilidad de Medicamentos , Concentración de Iones de Hidrógeno , Límite de Detección , Modelos Lineales , Análisis Multivariante , Reproducibilidad de los ResultadosRESUMEN
Simultaneous determination of miconazole (MIC), mometasone furaoate (MF), and gentamicin (GEN) in their pharmaceutical combination. Gentamicin determination is based on derivatization with of o-phthalaldehyde reagent (OPA) without any interference of other cited drugs, while the spectra of MIC and MF are resolved using both successive and progressive resolution techniques. The first derivative spectrum of MF is measured using constant multiplication or spectrum subtraction, while its recovered zero order spectrum is obtained using derivative transformation. Beside the application of constant value method. Zero order spectrum of MIC is obtained by derivative transformation after getting its first derivative spectrum by derivative subtraction method. The novel method namely, differential amplitude modulation is used to get the concentration of MF and MIC, while the novel graphical method namely, concentration value is used to get the concentration of MIC, MF, and GEN. Accuracy and precision testing of the developed methods show good results. Specificity of the methods is ensured and is successfully applied for the analysis of pharmaceutical formulation of the three drugs in combination. ICH guidelines are used for validation of the proposed methods. Statistical data are calculated, and the results are satisfactory revealing no significant difference regarding accuracy and precision.
Asunto(s)
Gentamicinas/análisis , Miconazol/análisis , Furoato de Mometasona/análisis , Espectrofotometría/métodos , Combinación de Medicamentos , Gentamicinas/química , Límite de Detección , Modelos Lineales , Miconazol/química , Furoato de Mometasona/química , Reproducibilidad de los ResultadosRESUMEN
The purpose of the present work was to develop a mucoadhesive thermoreversible nasal gel with a tailored gelling temperature to provide the prolonged contact between mometasone furoate and the nasal mucosa and in order to prevent drainage of the formulation. For this purpose, in situ gel containing a thermogelling polymer poloxamer 407 (Pluronic® F-127) and a mucoadhesive polymer Carbopol® 974P NF was prepared. In this content, formulations were designed to have gelation temperature below 34°C to obtain gelation at intranasal cavity. Evaluation of the prepared in situ gels was carried out by the determination of sol-gel transition temperature, rheological and mechanical characteristics, mucoadhesion strength, drug content, physicochemical stability, in vitro release profiles, and ex vivo permeation across sheep nasal mucosa of formulations. Consequently, the in situ gel (CP5) which had favorable gelation temperature (30.1 ± 0.24°C), rheological and mechanical characteristics, in vitro release profile (T%100 180 min), and mucoadhesion strength (0.289 ± 0.0069 mJ) was developed. Consequently, the in situ gel system has been concluded as a promising approach in order to improve the therapeutic effects of intranasal mometasone furoate administration.
Asunto(s)
Furoato de Mometasona/química , Rinitis Alérgica/tratamiento farmacológico , Administración Intranasal , Animales , Composición de Medicamentos , Liberación de Fármacos , Geles/química , Mucosa Nasal/metabolismo , Poloxámero/química , Ovinos , TemperaturaRESUMEN
OBJECTIVES: A new improved mometasone furoate (Elocon™) cream with an emulsification system that produces a stable emulsion has been developed. In order to register the product in various markets, it was essential to ensure the cream was topically well tolerated and that it was bioequivalent to the reference product. METHODS: Phase I clinical studies were performed to assess the local safety and tolerability upon multiple dosing of this new cream as well as to assess the single-dose bioequivalence relative to the marketed product. Bioequivalence was assessed using a vasoconstrictive assay (VCA) after a dose-duration pilot study was completed with the marketed Elocon cream. KEY FINDINGS: The new mometasone cream and its vehicle were nonirritating in healthy subjects during 21-day patch application (MCII <0.025). The positive control was moderately irritating in the same study. The pivotal VCA study enrolled 162 subjects with 105 detectors included in the analysis of bioequivalence. In the 105 detectors, the ratio (×100%) of AUEC values at ED50 for test vs. standard (90% CI) was 112.91% (105.55, 120.87), within the bioequivalence criteria of (80, 125). CONCLUSIONS: These studies supported the registration of reformulated mometasone cream in various markets.
Asunto(s)
Furoato de Mometasona/administración & dosificación , Absorción Cutánea/efectos de los fármacos , Vasoconstrictores/química , Vasoconstrictores/farmacología , Administración Cutánea , Bioensayo , Humanos , Furoato de Mometasona/química , Furoato de Mometasona/farmacología , Proyectos Piloto , Equivalencia TerapéuticaRESUMEN
The purpose of this research was to evaluate the effects of mPEG proportion and LA/GA ratio on degradation and release behavior of PLGA-mPEG microparticles prepared by the emulsion evaporation method. Mometasone furoate was employed as model drug and encapsulated into five types of PLGA-mPEG microparticles in the same molecular weight (Mw), but different in mPEG proportion or LA/GA ratio. All types of PLGA-mPEG microparticles showed similar drug encapsulation efficiency and particle mean size, but PLGA-mPEG microparticles with higher mPEG proportion showed a faster Mw reduction rate, mass loss rate and size decrease rate according to the in vitro degradation experiment, and also, a faster drug release rate according to the in vitro release experiment. On the other hand, higher LA/GA ratio in PLGA chain of PLGA-mPEG causes a slower Mw reduction rate, mass loss rate, size decrease rate, and thus, a slower drug release rate.
Asunto(s)
Portadores de Fármacos/química , Microesferas , Furoato de Mometasona/administración & dosificación , Poliésteres/química , Polietilenglicoles/química , Química Farmacéutica/métodos , Preparaciones de Acción Retardada , Composición de Medicamentos/métodos , Liberación de Fármacos , Emulsiones , Peso Molecular , Furoato de Mometasona/química , Tamaño de la PartículaRESUMEN
The Farnesoid X receptor (FXR) regulates bile salt, glucose and cholesterol homeostasis by binding to DNA response elements, thereby activating gene expression (direct transactivation). FXR also inhibits the immune response via tethering to NF-κB (tethering transrepression). FXR activation therefore has therapeutic potential for liver and intestinal inflammatory diseases. We aim to identify and develop gene-selective FXR modulators, which repress inflammation, but do not interfere with its metabolic capacity. In a high-throughput reporter-based screen, mometasone furoate (MF) was identified as a compound that reduced NF-κB reporter activity in an FXR-dependent manner. MF reduced mRNA expression of pro-inflammatory cytokines, and induction of direct FXR target genes in HepG2-GFP-FXR cells and intestinal organoids was minor. Computational studies disclosed three putative binding modes of the compound within the ligand binding domain of the receptor. Interestingly, mutation of W469A residue within the FXR ligand binding domain abrogated the decrease in NF-κB activity. Finally, we show that MF-bound FXR inhibits NF-κB subunit p65 recruitment to the DNA of pro-inflammatory genes CXCL2 and IL8. Although MF is not suitable as selective anti-inflammatory FXR ligand due to nanomolar affinity for the glucocorticoid receptor, we show that separation between metabolic and anti-inflammatory functions of FXR can be achieved.
Asunto(s)
Regulación de la Expresión Génica , Inflamación/genética , Inflamación/metabolismo , Furoato de Mometasona/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Animales , Antiinflamatorios/química , Antiinflamatorios/metabolismo , Antiinflamatorios/farmacología , Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Genes Reporteros , Células Hep G2 , Humanos , Ligandos , Ratones , Modelos Moleculares , Conformación Molecular , Simulación del Acoplamiento Molecular , Furoato de Mometasona/química , Furoato de Mometasona/farmacología , FN-kappa B/metabolismo , Regiones Promotoras Genéticas , Unión Proteica , Receptores Citoplasmáticos y Nucleares/química , Receptores Citoplasmáticos y Nucleares/genética , Factor de Transcripción ReIA/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
Co-administration of an inhaled corticosteroid and long acting beta agonist for chronic obstructive pulmonary disease has reduced mortality compared to either drug alone. This combination reduces exacerbations, hospitalization, emergency department visits and health care costs. A novel fixed-dose combination of the long acting beta-2 agonist salmeterol xinafoate (SX) and the corticosteroid mometasone furoate (MF) were prepared in a composite particle formulation as brittle matrix powder (BMP) and investigated for suitability as an inhaled combination product. In this study, BMP fixed dose combinations of SX and MF with or without stabilizing excipients (lactose, mannitol, glycine and trehalose) were prepared and characterized with respect to their thermal properties, morphology, aerodynamic performance and physical stability. BMP combination formulations of SX and MF exhibited improved aerodynamic properties when delivered by dry powder inhalation as compared to the micronized blends of the same substances. Aerodynamic evaluation was carried out by next generation pharmaceutical impactor (NGI) with a marketed DPI device. Results demonstrated that co-deposition occurred when SX and MF were formulated together as composite particles in a BMP, while physical blends resulted in inconsistent deposition and dose uniformity. As a result of the bottom-up particle engineering approach, combination BMP formulations allow for dual API composite formulations to be dispersed as aerosolized particles. Aerosolized BMP combination formulations resulted in delivered dose uniformity and co-deposition of each API. Further, an excipient-free formulation, BMP SXMF, delivered approximately 50% of the loaded dose in the respirable range and demonstrated stability at ambient conditions for 6months. Single dose 24-h pharmacokinetic studies in rats demonstrated that lung tissue deposition and blood circulation (AUC0-24h) of two APIs were higher for the BMP combination group exhibiting a significantly higher lung concentration of drugs than for the crystalline physical blend. While high system drug levels are generally undesirable in lung targeted therapies, high blood levels in this rodent study could be indicative of increased pulmonary tissue exposure using BMP formulations.